ArticleFrontiers in immunology2026
Small extracellular vesicles proteome reveals persistent inflammatory and coagulopathic dysregulation in long-COVID.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Post-acute sequelae of SARS-CoV-2 (PASC) or Long-COVID affects millions and remains mechanistically undefined due to its heterogeneous clinical presentation. Identifying robust biological signatures is essential for understanding disease mechanisms and improving diagnosis. Here, we investigated the protein cargo of plasma-derived small extracellular vesicles (SEVs) from PASC-positive and PASC-negative individuals to identify EV-linked biomarkers of Long-COVID. Methods: SEVs were isolated from EDTA plasma of PASC-positive (n=20) and PASC-negative (n=11) individuals using size-exclusion chromatography. SEV protein cargo was profiled across more than 5400 proteins using the Olink Explore HT platform. Results: PASC-positive patients commonly reported fatigue, shortness of breath, brain fog, sleep disruption, and mood changes. Proteomic analysis revealed 269 significantly dysregulated proteins, including 84 upregulated and 21 downregulated, with a fold change >2 in PASC. These differentially altered proteins were enriched in pathways related to coagulation, inflammation, apoptosis, fibrosis, extracellular matrix remodeling, mitochondrial dynamics, and immune activation. PASC-positive SEVs showed persistent increases in FN1, HCF-H, HGF, and IL-17RA, proteins previously dysregulated in acute COVID-19. These markers showed greater differences in SEVs than in matched plasma, particularly HGF and IL-17RA, which were significantly altered in SEVs but not in plasma. Conclusion: Proteomic alterations in SEVs from PASC patients highlight the inflammatory, thrombotic, and neurobiological dysregulation, underscoring the potential of SEVs as biomarkers and mechanistic drivers of long COVID.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.